Skip Ribbon Commands
Skip to main content
Sign In

Plasma Exchange for Specific Neurological Patients

FAST ROAD TO RESULTS FIRST-LINE THERAPY HOW IT WORKS SAFETY RESOURCES REFERENCES
®

How It Rapidly Reduces Disease Mediators

Plasma exchange is a well established immunomodulatory therapy that rapidly reduces disease mediators and circulating immune complexes to relieve symptoms of specific neurological patients.


(Saperstein and Barohn, 2004)







REDUCTION OF:

    

Pathological antibodies


    

Immunocomplexes, enhancing macrophage/monocyte function


    

Cytokines




REPLACEMENT OF:

    

Necessary plasma components


(Reeves and Winters, 2014)



THE RESULTS OF REDUCING DISEASE MEDIATORS




Plasma exchange is an immunotherapeutic that rapidly reduces disease mediators and circulating immune complexes to relieve symptoms. Improvement following plasma exchange can occur within a few days, much faster than other immunomodulating therapies.

(Saperstein 2004)




hjfkdghdfklgjhfd





PUTTING IT INTO ACTION






Plasma Exchange on the Spectra Optia® Apheresis System

  • Provides automated monitoring of the fluids used in the procedure which allows for the maintenance of fluid balance
  • Helps efficiently remove targeted blood components and achieve highly predictable results with the patented Automated Interface Management (AIM) system
  • Features a plasma removal efficiency (PRE)* up to 87 percent

    (Tormey, 2010)

  • Has a median procedure time of 1 hour and 45 minutes (based on analyzed data of more than 40,000 plasma exchange procedures)
  • Accommodates smaller patients and supports patient comfort and safety

*PRE is an established metric to analyze the performance of an apheresis device during a plasma exchange procedure



Learn More

Vascular Access

When tailoring a procedure for any patient, operators appreciate the flexibility of the multiple venous access options that can be used with the Spectra Optia system, including:
  • Peripheral venous access with single- or dual-needle options
  • Other venous access options, such as:
    • Central venous catheter
    • Arteriovenous (AV) fistula or AV graft
    • Implanted ports



HEAR FROM YOUR PEERS

Learn about the apheresis program at the University of California San Diego (UCSD), La Jolla, California.








Safety Information

Contraindications

  • No known contraindications for the system's use, except for those associated with all automated apheresis systems
  • The infusion of certain solutions and replacement fluids may be contraindicated in some patients

Possible patient reactions

  • Anxiety, headache, light-headedness, digital and/or facial paresthesia, fever, chills, hematoma, hyperventilation, nausea and vomiting, syncope (fainting), urticaria, hypotension and allergic reactions

Reactions to transfused blood products can include1

  • Fever, circulatory overload, shock, allergic reactions, alloimmunization, graft-versus-host disease and transmission of infection

Restricted to prescription use only

  • Operators must be familiar with the system's operating instructions
  • Procedures must be performed by qualified medical personnel
  • A supervisory practitioner may supervise from a physician office or other nonhospital space that is not officially part of the hospital campus as long as he or she remains immediately available2

1AABB (ed.), et al., Circular of Information for the Use of Human Blood and Blood Components. 2006, tenth edition, Council of Europe Publishing, Seattle, WA.

2American Society for Apheresis. Guidelines for therapeutic apheresis clinical privileges. J Clin Apher. 2007;22(3):181-182.




​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​